Studies indicate that treatment with 4-1BB agonistic antibodies effectively induces anti-tumor immunity (12), and co-stimulation through 4-1BB can further potentiate the reinvigoration of T cells mediated by PD-1 blockade (13). The gene discussed is TNFRSF9; the disease is neoplasm.